These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15474428)

  • 1. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast.
    Romero L; Klein L; Ye W; Holmes D; Soni R; Silberman H; Lagios MD; Silverstein MJ
    Am J Surg; 2004 Oct; 188(4):371-6. PubMed ID: 15474428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast.
    Lee LA; Silverstein MJ; Chung CT; Macdonald H; Sanghavi P; Epstein M; Holmes DR; Silberman H; Ye W; Lagios MD
    Am J Surg; 2006 Oct; 192(4):416-9. PubMed ID: 16978940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?
    Murphy CD; Jones JL; Javid SH; Michaelson JS; Nolan ME; Lipsitz SR; Specht MC; Lesnikoski BA; Hughes KS; Gadd MA; Smith BL
    Am J Surg; 2008 Oct; 196(4):566-8. PubMed ID: 18760400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index.
    Kelley L; Silverstein M; Guerra L
    Ann Surg Oncol; 2011 Feb; 18(2):459-62. PubMed ID: 20859695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?
    Chagpar AB; McMasters KM; Sahoo S; Edwards MJ
    Surgery; 2009 Oct; 146(4):561-7; discussion 567-8. PubMed ID: 19789013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic pathways in the evolution of breast ductal carcinoma in situ.
    Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
    J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.
    Vo TN; Meric-Bernstam F; Yi M; Buchholz TA; Ames FC; Kuerer HM; Bedrosian I; Hunt KK
    Am J Surg; 2006 Oct; 192(4):552-5. PubMed ID: 16978974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
    Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M
    Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast.
    Silverstein MJ; Lagios MD; Martino S; Lewinsky BS; Craig PH; Beron PJ; Gamagami P; Waisman JR
    J Clin Oncol; 1998 Apr; 16(4):1367-73. PubMed ID: 9552039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas.
    de Mascarel I; MacGrogan G; Mathoulin-Pélissier S; Soubeyran I; Picot V; Coindre JM
    Cancer; 2002 Apr; 94(8):2134-42. PubMed ID: 12001109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.
    Donker M; Litière S; Werutsky G; Julien JP; Fentiman IS; Agresti R; Rouanet P; de Lara CT; Bartelink H; Duez N; Rutgers EJ; Bijker N
    J Clin Oncol; 2013 Nov; 31(32):4054-9. PubMed ID: 24043739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
    Sanders ME; Schuyler PA; Dupont WD; Page DL
    Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast.
    Meijnen P; Oldenburg HS; Peterse JL; Bartelink H; Rutgers EJ
    Ann Surg Oncol; 2008 Jan; 15(1):235-43. PubMed ID: 17987342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?
    Yerushalmi R; Sulkes A; Mishaeli M; Neumann A; Dinerman M; Sulkes J; Rizel S; Yarom N; Gutman H; Fenig E
    Neoplasma; 2006; 53(6):507-10. PubMed ID: 17167720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.